Efficacy and safety of metolazone in renal failure and the nephrotic syndrome.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000378:metabolism; D004232:Diuretics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy; D005260:Female; D005919:Glomerular Filtration Rate; D006084:Graft Rejection; D006801:Humans; D007659:Ketones / Q000494:pharmacology / Q000627:therapeutic use; D007668:Kidney / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011188:Potassium / Q000097:blood; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D014527:Uric Acid / Q000097:blood
D004232:Diuretics; D007659:Ketones; D011799:Quinazolines; D013449:Sulfonamides; D014527:Uric Acid; D003404:Creatinine; D011188:Potassium